[Dual regulation effect of somatostatin on immunity in patients with severe sepsis caused by abdominal diseases]

What Was Tested

The paper reports a study of Somatostatin, published as a randomized controlled trial.

To investigate the effect of somatostatin on inflammatory immune disorders and prognosis in patients with severe sepsis caused by abdominal diseases.

Who Took Part

PubMed tags the participants as both men and women.

Fifty-three patients with severe abdominal sepsis (age > 18 years, APACHE-II score > 15) from June 2005 to June 2009 were randomly divided into Somatostatin group (n = 23) and SSC Group (n = 30).

Fifteen healthy volunteers of the same age range were chosen as Control group.

How the Study Was Run

The design is described as randomized.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The serum levels of interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) were determined by using ELISA.

CD(4)(+), CD(8)(+) T cell subsets were determined by fluorescence activated cell sorter(FACS) and CD(4)(+)/CD(8)(+) was calculated.

APACHE-II score was observed on admission (d1) and day 3, 7 and 14 after treatment.

Morality rates in 28 days in two groups were recorded.

What Was Measured

Topics PubMed links to this paper include APACHE, Case-Control Studies, Interleukin-10, Prognosis, Sepsis, Somatostatin and T-Lymphocyte Subsets.

What This Means in Plain Language

The paper is a randomized study of Somatostatin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Zhonghua wai ke za zhi [Chinese journal of surgery]), a journal based in China.

More context: the Somatostatin compound page, all human trials.